316 filings
Page 4 of 16
8-K
nx4pm5ahj00mzc
15 Aug 22
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
8:41am
8-K
bh8w7t2ntr4h4f
7 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
azbm46skcreovtw02
11 May 22
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
8:34am
DEFA14A
gj45 sef0py0iu
25 Apr 22
Additional proxy soliciting materials
8:33am
8-K
ozaod08f5
31 Mar 22
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
4:04pm
8-K
p8vvyi51xhdv 3h
28 Jan 22
Departure of Directors or Certain Officers
4:30pm
8-K
w5rv4
5 Jan 22
Company Presentation I January 2022Bellerophon Therapeutics
8:39am
8-K/A
fi0q2u q3
4 Jan 22
Departure of Directors or Certain Officers
4:10pm
8-K
ac4rd6m5sans9wzfb
17 Dec 21
Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial
8:29am
8-K
rwk9dk77bterzi8nuh
15 Nov 21
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results
9:02am
8-K
1vqud8u 92il3ti4r
12 Nov 21
Departure of Directors or Certain Officers
8:24am
8-K
sdfgfte8u2eldxq5g
12 Oct 21
Departure of Directors or Certain Officers
4:59pm
8-K
07x8n8qg0lnikap6 610
6 Oct 21
Departure of Directors or Certain Officers
8:58am
8-K
tuhzbrep
31 Aug 21
Departure of Directors or Certain Officers
5:00pm
8-K
5jo4f iood
5 Aug 21
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results
8:29am